The Lithuanian company is looking for a partnership to develop an in vivo implantable arterial blood pressure biosensor.

Short summary A Lithuanian company specializing in medical devices is looking for a partner to create an implantable prototype of a medical device for continuous measurement of arterial blood pressure. Company is looking for industrial R&D partners under cooperation sought

Full description Idea and conceptualization: 1.Minimally invasive implantable biosensor. 2.The physical dimensions of the sensor prototype already have been achieved, which are optimal for biological use, and an original in vivo implantation procedure has been developed. 2. During implantation, be individually calibrated with a reference invasive blood pressure measurement. 3. Biocompatible materials for in vivo implantation are used for the prototype. Biosensor prototype development stage. The functionalized biosensor prototype is already manufactured using 3D printing technology (functional sensor parts are the size of dozens of microns) and are used elements of AM. Prototype is tested (> 1000K) in hemodynamic laboratory circuity. The sensor prototype has an energy harvesting feature. The aim of the current stage is to perform a sensor prototype in vivo implantation and constantly to measure blood pressure (sheep) up to 1 month time. An external microcontroller is prepared for the experiment, which will not be further developed. In vivo experiment is scheduled in September- October 2022 in a project with the Biological Research Center of the Lithuanian Health Sciences University. During the experiment required by partner parameters of prototype sensor could be registered that would be serve in design and development of a prototype microcontroller with the NFC feature and extending to IoT.

Advantages and innovations In the developed world, arterial hypertension is estimated to affect one in 4 men and one in 5 women. Often, patients with arterial hypertension do not feel symptoms, so the disease remains undiagnosed or is diagnosed late with complications. However, due to insufficient or inadequate monitoring of blood pressure, without taking into account changes in blood pressure during exercise and emotional exercise, the correction of blood pressure remains inadequate and insufficient. Looking at the recent epidemic-quarantine period, and the risk of recurrence when access to a doctor's consultation may be limited, remote arterial blood pressure monitoring and treatment correction may be effective and efficient in a variety of settings. The development of a implantable blood pressure measurement medical device would provide one of the most important human physiological parameters in real time. In the future, the treatment of hypertension could be objectively individualized.

Contact / source: NEXT EEN Widgets (europa.eu)